Tribulations or triumphs in prostate cancer immunotherapy: On the road to victory?

Expert Review of Anticancer Therapy

Volumn 8, Issue 3, 2008, Pages 465-474

  Slovin, Susan F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Checkpoint molecule; CTLA 4; Cytokine; Fowlpox; G VAX; Monoclonal antibody; PSA; PSADT; PSAM; Sipuleucel; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; BCG VACCINE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; FOWLPOX VIRUS VECTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONTANIDE ISA 51; PLACEBO; POXVIRUS VECTOR; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; QS 21; RETROVIRUS VECTOR; SIPULEUCEL T; TUMOR CELL VACCINE; VACCINIA VACCINE; VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; AUTOIMMUNITY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LEUKAPHERESIS; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PROSTATE CANCER; REVIEW; RIGOR; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 45249106792     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.3.465     Document Type: Review

References (42)

1. Shah RB, Mehra P, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 64, 9209-9216 (2004).
2. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 12, 1665-1671 (2006).
3. Kim JH, Dhanasekaran SM, Mehra R et al. Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancar Res. 67, 229-239 (2007).
4. Slovin SF. How to channel a minimal response for maximal outcome. Curr. Opin. Urol. 16, 179-185 (2006).
5. Slovin SF, Ragupathi G, Adluri S et al. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo hexasaccharide conjugate in man. Proc. Natl Acad. Sci USA 6, 5710-5715 (1999).
6. Slovin SF, Ragupathi G, Musselli C et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N- acetylgalactosamine-O-serine/threonine (Tn) conjugate. Vaccine J. Clin. Oncol. 21, 4292-4298 (2003).
7. Slovin SF, Ragupathi G, Fernandez C et al. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS-21. Vaccine 23, 3114-3122 (2005).
8. Slovin SF, Ragupathi G, Fernandez C et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 54, 694-702 (2005).
9. Pound CR, Partin AW, Eisenberger MA et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591-1597. (1999).
10. Slovin SF, Ragupathi G, Fernandez C, Diani M et al. A polyvalent vaccine for high risk prostate patients. Are more antigens better? Cancer Immunol. Immunother. 56, 1921-1930 (2007).
11. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. 62, 5770-5777 (2002).
12. Eder JP, Kantoff PW, Roper K et al. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632-1638 (2000).
13. Kaufman HL, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22, 2122-2132 (2004).
14. Kaufman HL, Wang W, Manob J et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow-up clinical results from ECOG 7897. J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 4501).
15. Hodge JW, Sabzevari H, Yafal AG et al. A triad of co-stimulatory molecules synergizes to amplify T-cell activation. Cancer Res. 59, 5800-5807 (1999).
16. Gulley J, Todd N, Dahut W et al. A Phase II study of PROSTVAC-VF vaccine, and the role of GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC). J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 2504).
17. Kantoff PW, Globe LM, Tannenbaum SI et al. Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC). J. Clin. Oncol. 24(Suppl. 18), (2006) (Abstract 2501).
18. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin. Cancer Res. 13, 3776-3782 (2007).
19. Arlen PM, Skarupa L, Pazdur M et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol. 178, 1515-1520 (2007).
20. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539-3543 (1993).
21. Eager R, Nemunaitis. GM-CSF gene-transduced tumor vaccines. Mol. Ther. 12, 18-27 (2005).
22. Simons JW, Mikhak B, Chang J-F et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160-5168 (1999).
23. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546 (1997).
24. Berns AJ, Clift S, Cohen LK et al. Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 6, 347-368 (1995).
25. Simons JW, Carducci MA, Mikhak B et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin. Cancer Res. 12, 3394-3401 (2006).
26. Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor - secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13, 3883-3891 (2007).
27. Thomas-Kaskel A-K, Zeiser R, Jochim R et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J. Cancer 119, 2428-2434 (2006).
28. Small EJ, Fratesi O, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903 (2000).
29. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094 (2006).
30. Leach DM, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
31. Chambers CA, Kuhns MS, Allison JP Cytotoxic T lymphocyte antigen-4(CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc. Natl Acad. Sci. USA 96, 8603-8608 (1999).
32. Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl Acad. Sci. USA 96, 15074-15079 (1999).
33. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity inpatients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12, 1005-1016 (2005).
34. Blansfield JA, Beck KE, Tran K et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 28, 593-598 (2005).
35. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043-6053 (2005).
36. Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen 4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc. Natl Acad. Sci. USA 99, 3013-3017 (2002).
37. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
38. van Elsas A, Sutmuller RP, Hurwitz AA. Elucidating the autoimmune and anti-tumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194, 481-489 (2001).
39. Camacho LH, Ribas A, Glaspy JA et al. Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. 22(Suppl. 164) (2004) (Abstract 2505).
40. Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100(8), 4712-4717 (2003).
41. Gerritsen W, Van Den Eertwegh AJ, De Gruijl T et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patient with hormone-refractory prostate cancer (mHRPC). Proc. Am. Soc. Clin. Oncol. 24(Suppl. 100) (2006) (Abstract 2500).
42. Sharp HJ, Wansley EK, Garnett T et al. Synergistic antitumor activity of immune strategies combined with radiation. Front. Biosci. 12, 4900-4910 (2007).